CaIPLA2 Polyclonal Antibody, Cy5 Conjugated
Product Specifications
Background
Catalyzes the release of fatty acids from phospholipids. It has been implicated in normal phospholipid remodeling, nitric oxide-induced or vasopressin-induced arachidonic acid release and in leukotriene and prostaglandin production. May participate in fas mediated apoptosis and in regulating transmembrane ion flux in glucose-stimulated B-cells. Has a role in cardiolipin (CL) deacylation. Required for both speed and directionality of monocyte MCP1/CCL2-induced chemotaxis through regulation of F-actin polymerization at the pseudopods. Isoform ankyrin-iPLA2-1 and isoform ankyrin-iPLA2-2, which lack the catalytic domain, are probably involved in the negative regulation of iPLA2 activity.
Synonyms
GVI; PLA2; INAD1; NBIA2; iPLA2; NBIA2A; NBIA2B; PARK14; PNPLA9; CaI-PLA2; IPLA2-VIA; iPLA2beta; 85/88 kDa calcium-independent phospholipase A2; Group VI phospholipase A2; GVI PLA2; Intracellular membrane-associated calcium-independent phospholipase A2 beta; iPLA2-beta; Patatin-like phospholipase domain-containing protein 9; PLA2G6; PLPLA9
Gene ID
8398
Swiss Prot
O60733
Cellular Locus
Cytoplasm, Cell membrane
Host
Rabbit
Immunogen
651-750/806
Target
CaI-PLA2
Clonality
Polyclonal
Isotype
IgG
Conjugation
Cy5
Source
KLH conjugated synthetic peptide derived from human CaI-PLA2/PLA2G6
Applications
WB, IF (IHC-P), IF (IHC-F), IF (ICC)
Purification
Purified by Protein A.
Excitation Emission
625,650nm/670nm
Concentration
1µg/µl
Dilution
WB (1:300-5000), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Gene ID URL
8398
Predicted Cross Reactivity
Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Rabbit
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
